These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 32734002)

  • 1. The direct-medical costs associated with interferon-based treatment for Hepatitis C in Vietnam.
    Nguyen HA; Cooke GS; Day JN; Flower B; Phuong LT; Hung TM; Dung NT; Khoa DB; Hung LM; Kestelyn E; Thwaites GE; Chau NVV; ; Turner HC
    Wellcome Open Res; 2019; 4():129. PubMed ID: 32734002
    [No Abstract]   [Full Text] [Related]  

  • 2. Present, old and future strategies for anti-HCV treatment in patients infected by genotype-1: estimation of the drug costs in the Calabria Region in the era of the directly acting antivirals.
    Strazzulla A; Costa C; Pisani V; De Maria V; Giancotti F; Di Salvo S; Parisi SG; Basso M; Franzetti MM; Marascio N; Liberto MC; Barreca GS; Lamberti AG; Zicca E; Postorino MC; Matera G; Focà A; Torti C
    BMC Infect Dis; 2014; 14 Suppl 5(Suppl 5):S3. PubMed ID: 25236374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of interferon free regimens on clinical and cost outcomes for chronic hepatitis C genotype 1 patients.
    Younossi ZM; Singer ME; Mir HM; Henry L; Hunt S
    J Hepatol; 2014 Mar; 60(3):530-7. PubMed ID: 24269472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Micro-costing analysis of guideline-based treatment by direct-acting agents: the real-life case of hepatitis C management in Brazil.
    Perazzo H; Jorge MJ; Silva JC; Avellar AM; Silva PS; Romero C; Veloso VG; Mujica-Mota R; Anderson R; Hyde C; Castro R
    BMC Gastroenterol; 2017 Nov; 17(1):119. PubMed ID: 29169329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Shepherd J; Jones J; Takeda A; Davidson P; Price A
    Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic evaluation of pegylated interferon plus ribavirin for treatment of chronic hepatitis C in Thailand: genotype 1 and 6.
    Kapol N; Lochid-Amnuay S; Teerawattananon Y
    BMC Gastroenterol; 2016 Aug; 16(1):91. PubMed ID: 27492396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-Utility Analysis of Direct-Acting Antivirals for Treatment of Chronic Hepatitis C Genotype 1 and 6 in Vietnam.
    Due OT; Thakkinstian A; Thavorncharoensap M; Sobhonslidsuk A; Wu O; Phuong NK; Chaikledkaew U
    Value Health; 2020 Sep; 23(9):1180-1190. PubMed ID: 32940236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world treatment for chronic hepatitis C infection in Germany: Analyses from drug prescription data, 2010-2015.
    Zimmermann R; Kollan C; Ingiliz P; Mauss S; Schmidt D; Bremer V
    J Hepatol; 2017 Jul; 67(1):15-22. PubMed ID: 28189752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug Pricing Evolution in Hepatitis C.
    Vernaz N; Girardin F; Goossens N; Brügger U; Riguzzi M; Perrier A; Negro F
    PLoS One; 2016; 11(6):e0157098. PubMed ID: 27310294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferon alpha (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and economic evaluation.
    Shepherd J; Jones J; Hartwell D; Davidson P; Price A; Waugh N
    Health Technol Assess; 2007 Mar; 11(11):1-205, iii. PubMed ID: 17346498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of sofosbuvir based direct-acting antiviral regimens for chronic hepatitis C virus genotype 6 patients: Real-world experience in Vietnam.
    Nguyen DT; Tran TTT; Nghiem NM; Le PT; Vo QM; Day J; Rahman M; Le HM
    PLoS One; 2020; 15(5):e0233446. PubMed ID: 32433676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in previously untreated chronic hepatitis C genotype 1 patients.
    Cure S; Bianic F; Gavart S; Curtis S; Lee S; Dusheiko G
    J Med Econ; 2014 Jan; 17(1):65-76. PubMed ID: 24160335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Should we await IFN-free regimens to treat HCV genotype 1 treatment-naive patients? A cost-effectiveness analysis (ANRS 95141).
    Deuffic-Burban S; Schwarzinger M; Obach D; Mallet V; Pol S; Pageaux GP; Canva V; Deltenre P; Roudot-Thoraval F; Larrey D; Dhumeaux D; Mathurin P; Yazdanpanah Y
    J Hepatol; 2014 Jul; 61(1):7-14. PubMed ID: 24650691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Direct medical care costs among pegylated interferon plus ribavirin-treated and untreated chronic hepatitis C patients.
    Solomon M; Bonafede M; Pan K; Wilson K; Beam C; Chakravarti P; Spiegel B
    Dig Dis Sci; 2011 Oct; 56(10):3024-31. PubMed ID: 21717127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.
    Shepherd J; Brodin H; Cave C; Waugh N; Price A; Gabbay J
    Health Technol Assess; 2004 Oct; 8(39):iii-iv, 1-125. PubMed ID: 15461877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiviral Therapy in Patients with Hepatitis C Virus-Induced Cirrhosis.
    Bailly F; Pradat P; Virlogeux V; Zoulim F
    Dig Dis; 2015; 33(4):613-23. PubMed ID: 26159282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autoantibodies to cytoplasmic rods and rings in patients with hepatitis C virus infection treated with direct-acting antivirals: The role of prior treatment with interferon plus ribavirin.
    Alsius M; Ferri MJ; Buxó M; López C; Serra I; Queralt X; Acero D
    Gastroenterol Hepatol; 2019 Feb; 42(2):82-89. PubMed ID: 30446175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sofosbuvir-Based Regimens for Chronic Hepatitis C in a Well-Insured U.S. Population: Patient Characteristics, Treatment Adherence, Effectiveness, and Health Care Costs, 2013-2015.
    Yin S; Barker L; White JZ; Jiles RB
    J Manag Care Spec Pharm; 2019 Feb; 25(2):195-210. PubMed ID: 30698086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing the burden of illness of chronic hepatitis C and impact of direct-acting antiviral use on healthcare costs in Medicaid.
    Roebuck MC; Liberman JN
    Am J Manag Care; 2019 Jun; 25(8 Suppl):S131-S139. PubMed ID: 31211526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Where are the children in national hepatitis C policies? A global review of national strategic plans and guidelines.
    Malik F; Bailey H; Chan P; Collins IJ; Mozalevskis A; Thorne C; Easterbrook P
    JHEP Rep; 2021 Apr; 3(2):100227. PubMed ID: 33665586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.